EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended new therapies from Hansoh, Innovent and AstraZeneca at its November meeting, according to a data byte summary. The update highlights continued activity in Europe’s regulatory pipeline for oncology and other specialty areas, with multiple Chinese originators represented among the recommended medicines. For biotech stakeholders, CHMP opinions often precede formal European Commission decisions and can shift development and commercial planning. The note underscores how originator portfolios from China continue to land in late-stage review alongside established global pharma. —